Intraocular Lymphoma

  • Hiroshi Goto


Intraocular lymphoma is a relatively rare and highly malignant disease. The so-called primary intraocular lymphoma (PIOL) may occur prior or subsequent to primary central nervous system (CNS) lymphoma. Intraocular lymphoma is easily misdiagnosed as uveitis, and the issue of masquerade syndrome tends to delay diagnosis and treatment. The prognosis of visual function is similar to other fundus diseases; visual function is often well preserved if the lesion does not involve the macula or optic nerve. However, CNS lymphoma occurs in 65–90 % of the patients [1, 2], and the prognosis of survival is very poor with 5-year survival rate of 30–60 % [3, 4].


Retinal Pigment Epithelium Primary Central Nervous System Lymphoma Cystoid Macular Edema Central Nervous System Lymphoma Central Nervous System Lesion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Baehring JM, Androudi S, Longtine JJ, et al. Analysis of clonal immunoglobulin heavy chain rearrangements in ocular lymphoma. Cancer. 2005;104:591–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Chan CC, Gonzales JA. Primary intraocular lymphoma. Hackensack: World Scientific; 2007. p. 19–42.CrossRefGoogle Scholar
  3. 3.
    Chan CC, Rubenstein JL, Coupland SE, et al. Primary vitreoretinal lymphoma: a report from an international primary central nervous system lymphoma collaborative group symposium. Oncologist. 2011;16:1589–99.PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Kimura K, Usui Y, Goto H, et al. Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma. Jpn J Ophthalmol. 2012;56:383–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Coupland SE, Chan CC, Smith J. Pathophysiology of retinal lymphoma. Ocul Immunol Inflamm. 2009;17:227–37.PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Coupland SE, Heimann H, Bechrakis NE. Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features. Graefes Arch Clin Exp Ophthalmol. 2004;241:901–13.CrossRefGoogle Scholar
  7. 7.
    Freeman LN, Schachat AP, Knox DL, et al. Clinical features laboratory investigations, and survival in ocular reticulum sarcoma. Ophthalmology. 1987;94:1631–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Eby NL, Grufferman S, Flannelly CM, et al. Increasing incidence of primary brain lymphoma in the US. Cancer. 1988;62:2461–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Velez G, Chan CC, Csaky KG. Fluorescein angiographic findings in primary intraocular lymphoma. Retina. 2002;22:37–43.CrossRefPubMedGoogle Scholar
  10. 10.
    Whitcup SM, de Smet MD, Rubin BI, et al. Intraocular lymphoma. Clinical and histopathologic diagnosis. Ophthalmology. 1993;100:1399–406.CrossRefPubMedGoogle Scholar
  11. 11.
    Liu TY, Ibrahim M, Bittencourt M, et al. Retinal optical coherence tomography manifestations of intraocular lymphoma. J Ophthalmic Inflamm Infect. 2012;2:215–8.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Casady M, Faia L, Nazemzadeh M, Nussenblatt R, Chan CC, Sen HN. Fundus autofluorescence patterns in primary intraocular lymphoma. Retina. 2014;34(2):366–72.Google Scholar
  13. 13.
    Cummings TJ, Stenzel TT, Klintworth G, et al. Primary intraocular T-cell-rich large B-cell lymphoma. Arch Pathol Lab Med. 2005;129:1050–3.PubMedGoogle Scholar
  14. 14.
    Gametchu B. Glucocorticoid receptor-like antigen in lymphoma cell membrane: correlation to cell lysis. Science. 1987;236:456–61.CrossRefPubMedGoogle Scholar
  15. 15.
    Grimm SA, McCannel CA, Omuro AM, et al. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology. 2008;71:1355–60.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Berenbom A, Davila RM, Lin HS, et al. Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy. Eye (Lond). 2007;21:1198–201.CrossRefGoogle Scholar
  17. 17.
    Ferrei AJ, Blay JY, Reni M, et al. Relevance of intraocular involvement in the management of primary central nervous system lymphomas. Ann Oncol. 2002;13:531–8.CrossRefGoogle Scholar
  18. 18.
    Isobe K, Ejima Y, Tokumaru S, et al. Treatment of primary intraocular lymphoma with radiation therapy: a multi-institutional survey in Japan. Leuk Lymphoma. 2006;47:1800–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Fishburne BC, Wilson DJ, Rosenbaum JT, et al. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol. 1997;115:1152–6.CrossRefPubMedGoogle Scholar
  20. 20.
    de Smet MD, Vancs VS, Kohler D, et al. Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma. Br J Ophthalmol. 1999;83:448–51.PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Frenkel S, Hendler K, Siegal T, et al. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol. 2008;92:383–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Rajagopal R, Harbour JW. Diagnostic testing and treatment choices in primary vitreoretinal lymphoma. Retina. 2011;31:435–40.CrossRefPubMedGoogle Scholar
  23. 23.
    Kitzmann AS, Pulido JS, Mohney BG. Intraocular use of rituximab. Eye (Lond). 2007;21:1524–7.CrossRefGoogle Scholar
  24. 24.
    Ohguro N, Hashida N, Tano Y. Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma. Arch Ophthalmol. 2008;126:1002–3.CrossRefPubMedGoogle Scholar
  25. 25.
    Batchelor TT, Kolak G, Ciordia R, et al. High-dose methotrexate for intraocular lymphoma. Clin Cancer Res. 2003;9:711–5.PubMedGoogle Scholar
  26. 26.
    Taoka K, Yamamoto G, Kaburaki T, et al. Treatment of primary intraocular lymphoma with rituximab, high dose methotrexate, procarbazine, and vincristine chemotherapy, reduced whole-brain radiotherapy, and local ocular therapy. Br J Haematol. 2012;157:252–4.CrossRefPubMedGoogle Scholar
  27. 27.
    Neuwelt EA, Goldman DL, Dahlborg SA, et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol. 1991;9:1580–90.PubMedGoogle Scholar
  28. 28.
    Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol. 1998;16:859–63.PubMedGoogle Scholar
  29. 29.
    Prica A, Chan K, Cheung MC. Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a decision analysis. Br J Haematol. 2012;158:600–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer India 2016

Authors and Affiliations

  1. 1.Department of OphthalmologyTokyo Medical UniversityTokyoJapan

Personalised recommendations